NEW YORK, May 6, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including World Acceptance Corp. (NASDAQ: WRLD), Celladon Corp. (NASDAQ: CLDN), WuXi PharmaTech (NYSE: WX), AtriCure, Inc. (NASDAQ: ATRC), and AAC Holdings, Inc. (NYSE: AAC). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
WRLD Research Report: ( http://get.analystsreview.com/pdf/?c=World%20Acceptance&d=06-May-2015&s=WRLD ),
CLDN Research Report: ( http://get.analystsreview.com/pdf/?c=Celladon%20Corporation&d=06-May-2015&s=CLDN ),
WX Research Report: ( http://get.analystsreview.com/pdf/?c=WuXi%20PharmaTech&d=06-May-2015&s=WX ),
ATRC Research Report: ( http://get.analystsreview.com/pdf/?c=AtriCure&d=06-May-2015&s=ATRC ),
AAC Research Report: ( http://get.analystsreview.com/pdf/?c=AAC%20Holdings&d=06-May-2015&s=AAC ).
============
--
Analyst Update: Earnings and Operational Updates, and Drug Trial Results
Reviewed by: Rohit Tuli, CFA®
U.S. stocks tumbled on Tuesday as investors turned nervous amid a sharp increase in the US trade deficit gap. The NASDAQ Composite slipped 1.55%, to close at 4,939.33, the S&P 500 declined by 1.18%, to 2,089.46, and the Dow Jones Industrial Average end the session at 17,928.20, down 0.79%. European stocks closed lower on Tuesday amid increasing uncertainty over Greece's future. Germany's DAX 30 fell 2.51%, France's CAC 40 declined 2.12%, and the London's FTSE 100 closed 0.84% lower on Tuesday. Meanwhile, Asian markets drifted on Tuesday as the Reserve Bank of Australia cut interest rates and factory output in China stumbled. The Shanghai Composite; Australia's S&P ASX and Hong Kong's Hang Seng index all fell on Tuesday.
On April 30, 2015, World Acceptance Corporation reported financial results for its fourth fiscal quarter and twelve months ended March 31, 2015. Net income for Q4 FY 2015 increased 24.5% YoY to $48.5 million. Net income per diluted share increased 43.2% YoY to $5.34. Total revenues increased to $173.0 million in Q4 FY 2015 compared with $161.9 million reported in Q4 FY 2014.
Celladon Corporation announced on April 26, 2015, that its Phase 2b CUPID2 trial did not meet its primary and secondary endpoints. CUPID2 is a randomized, double-blind, placebo-controlled, multinational trial evaluating a single, one-time, intracoronary infusion of the cardiovascular gene therapy agent MYDICAR versus placebo added to a maximal, optimized heart failure drug and device regimen.
WuXi Biologics, a wholly owned subsidiary of WuXi PharmaTech, announced today that construction has begun on a new $150 million biologics manufacturing facility in Wuxi city. When complete, this new facility will be the largest mammalian cell culture manufacturing facility using disposable bioreactors in the world.
On April 29, 2015, AtriCure, Inc. announced Q1 2015 financial results. Revenue for Q1 2015 was $29.9 million, an increase of $5.0 million or 20.3% YoY. Domestic revenue increased 26.3% YoY to $22.9 million during the quarter, while international revenue was $7.0 million, an increase of 3.9% YoY. International revenue growth was driven primarily by increases in product sales in Europe.
AAC Holdings, Inc. announced its Q1 2015 financial results on April 29, 2015. Revenue in Q1 2015 increased to $42.8 million, compared with $30.1 million in the prior-year period and $37.2 million in the Q4 2014. Net income available to stockholders increased to $2.0 million, or $0.10 per diluted share, in Q1 2015 compared with $1.0 million, or $0.07 per diluted share, in the prior-year period and $3.1 million, or $0.15 per diluted share, in Q4 2014.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider, represented by a registered analyst has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
